

# Imre Romics

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1482564/publications.pdf>

Version: 2024-02-01

60  
papers

1,277  
citations

304368

22  
h-index

377514

34  
g-index

75  
all docs

75  
docs citations

75  
times ranked

1973  
citing authors

#	ARTICLE	IF	CITATIONS
1	Urinary incontinence and voiding dysfunction after radical retropubic prostatectomy (prospective) Tj ETQq1 1 0.784314 rgBT /Overlo	0.8	133
2	Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Science, 2010, 101, 1300-1308.	1.7	92
3	Gene network and canonical pathway analysis in prostate cancer: a microarray study. Experimental and Molecular Medicine, 2008, 40, 176.	3.2	56
4	Treatment and Outcome of Vaseline-Induced Sclerosing Lipogranuloma of the Penis. Urology, 2008, 71, 1132-1137.	0.5	51
5	Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. Pharmacogenetics and Genomics, 2011, 21, 673-678.	0.7	50
6	The prognostic value of cadherin switch in bladder cancer. Oncology Reports, 2010, 23, 1125-32.	1.2	48
7	Angiogenic Switch of Angiotensin-Tie2 System and Its Prognostic Value in Bladder Cancer. Clinical Cancer Research, 2008, 14, 8253-8262.	3.2	44
8	Long-Term Psychological and Sexual Outcomes of Severe Penile Hypospadias Repair. Journal of Sexual Medicine, 2011, 8, 1529-1539.	0.3	43
9	Management of Congenital Penile Curvature. Journal of Urology, 2008, 179, 1495-1498.	0.2	41
10	Prognostic Factors and Survival of Renal Clear Cell Carcinoma Patients with Bone Metastases. Pathology and Oncology Research, 2010, 16, 29-38.	0.9	40
11	Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer. International Journal of Cancer, 2012, 130, 2922-2929.	2.3	40
12	Analysis of Risk Factors for Urinary Incontinence after Radical Prostatectomy. Urologia Internationalis, 2007, 78, 202-207.	0.6	39
13	Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. International Journal of Cancer, 2011, 128, 1486-1492.	2.3	39
14	Rs710521 [A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk. Archives of Toxicology, 2010, 84, 967-978.	1.9	37
15	Serum Levels of Angiogenic Factors and their Prognostic Relevance in Bladder Cancer. Pathology and Oncology Research, 2009, 15, 193-201.	0.9	32
16	Rs11892031 [A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk. Archives of Toxicology, 2012, 86, 1369-1378.	1.9	32
17	Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathology and Oncology Research, 2007, 13, 187-194.	0.9	31
18	High insulin-like growth factor mRNA-binding protein 3 (IMP3) protein expression is associated with poor survival in muscle-invasive bladder cancer. BJU International, 2012, 110, E308-17.	1.3	31

#	ARTICLE	IF	CITATIONS
19	Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. <i>BJU International</i> , 2011, 107, 1069-1073.	1.3	28
20	Expression of Claudins and Their Prognostic Significance in Noninvasive Urothelial Neoplasms of the Human Urinary Bladder. <i>Journal of Histochemistry and Cytochemistry</i> , 2011, 59, 932-941.	1.3	28
21	Overexpression of CD24, c-myc and Phospholipase 2A in Prostate Cancer Tissue Samples Obtained by Needle Biopsy. <i>Pathology and Oncology Research</i> , 2009, 15, 279-283.	0.9	27
22	β-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression. <i>BJU International</i> , 2010, 105, 716-722.	1.3	25
23	The application of adjuvant autologous intravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial. <i>Journal of Translational Medicine</i> , 2010, 8, 54.	1.8	25
24	Claudins and Ki-67. <i>Journal of Histochemistry and Cytochemistry</i> , 2011, 59, 1022-1030.	1.3	16
25	Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival. <i>Pathology and Oncology Research</i> , 2017, 23, 643-650.	0.9	16
26	Phytotherapy Adds to the Therapeutic Armamentarium for the Treatment of Mild-To-Moderate Lower Urinary Tract Symptoms in Men. <i>Urologia Internationalis</i> , 2020, 104, 333-342.	0.6	16
27	A Special Terpene Combination (Rowatinex <sup>®</sup> ) Improves Stone Clearance after Extracorporeal Shockwave Lithotripsy in Urolithiasis Patients: Results of a Placebo-Controlled Randomised Controlled Trial. <i>Urologia Internationalis</i> , 2011, 86, 102-109.	0.6	14
28	Urinary bladder cancer risk in relation to a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor-binding protein-3 (IGFBP3) gene. <i>Archives of Toxicology</i> , 2012, 86, 195-203.	1.9	14
29	European Study of Radical Prostatectomy: time trends in Europe, 1993-2005. <i>BJU International</i> , 2007, 100, 22-25.	1.3	13
30	Signet-ring cell carcinoma arising from the urinary bladder. <i>Canadian Journal of Urology</i> , 2008, 15, 4266-8.	0.0	13
31	Genetic Profile of Bone Metastases in Renal Cell Carcinoma. <i>European Urology</i> , 2004, 45, 320-324.	0.9	12
32	Circulating Angiostatin, bFGF, and Tie2/TEK Levels and Their Prognostic Impact in Bladder Cancer. <i>Urology</i> , 2012, 80, 737.e13-737.e18.	0.5	12
33	Expression of p21waf1/cip1, p27kip1, p63 and Androgen Receptor in Low and High Gleason Score Prostate Cancer. <i>Pathology and Oncology Research</i> , 2008, 14, 307-311.	0.9	11
34	The role of alpha-adrenoreceptors in the treatment of urological diseases. <i>Neurochemistry International</i> , 2007, 51, 328-331.	1.9	10
35	T2a Transitional Cell Carcinoma of the Bladder: Long-term Experience With Intravesical Immunoprophylaxis With Bacillus Calmette-guerin. <i>Journal of Urology</i> , 2003, 169, 931-935.	0.2	9
36	A novel videomicroscopic technique for studying rat ureteral peristalsis in vivo. <i>World Journal of Urology</i> , 2009, 27, 265-270.	1.2	9

#	ARTICLE	IF	CITATIONS
37	Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma. <i>Clinical Rheumatology</i> , 2005, 24, 319-323.	1.0	8
38	The influence of expertise of the surgical pathologist to undergrading, upgrading, and understaging of prostate cancer in patients undergoing subsequent radical prostatectomy. <i>International Urology and Nephrology</i> , 2014, 46, 371-377.	0.6	8
39	Clinical symptoms related to renal cell carcinoma are independent prognostic factors for intraoperative complications and overall survival. <i>International Urology and Nephrology</i> , 2009, 41, 835-842.	0.6	7
40	The technique of ultrasound guided prostate biopsy. <i>World Journal of Urology</i> , 2004, 22, 353-356.	1.2	6
41	E-Cadherin expression in transitional cell carcinomas. <i>Pathology and Oncology Research</i> , 2006, 12, 73-77.	0.9	6
42	Improving Stone Clearance After Extracorporeal Shock Wave Lithotripsy in Urolithiasis Patients by a Special Terpene Combination (RowatinexA®): Results of a Placebo-Controlled, Randomized Trial. <i>European Urology Supplements</i> , 2010, 9, 819-825.	0.1	5
43	Changes in Erythrocyte Transmethylation Ability are Predictive Factors for Tumor Prognosis in Prostate Cancer. <i>Croatica Chemica Acta</i> , 2011, 84, 127-131.	0.1	5
44	A novel approach to the treatment of benign prostatic hyperplasia. <i>BJU International</i> , 2006, 97, 1252-1255.	1.3	4
45	The Guestbook of the Urology Department of Semmelweis University in Budapest: a Mirror of International Contacts. <i>Journal of Urology</i> , 2007, 178, 409-413.	0.2	4
46	Penis covering and simultaneous urethral replacement by scrotal skin for severe penile and urethral necrosis. <i>International Urology and Nephrology</i> , 2009, 41, 537-540.	0.6	4
47	Changes of protein expression in prostate cancer having lost its androgen sensitivity. <i>International Urology and Nephrology</i> , 2015, 47, 1149-1154.	0.6	4
48	A case of bilateral testicular lymphoma. <i>Pathology and Oncology Research</i> , 1999, 5, 152-154.	0.9	3
49	Improving diagnostic accuracy of prostate carcinoma by systematic random map-biopsy. <i>Pathology and Oncology Research</i> , 2000, 6, 111-113.	0.9	3
50	Voiding Symptoms and Urodynamic Findings in Patients with Modified Ileal Neobladder. <i>Pathology and Oncology Research</i> , 2009, 15, 307-313.	0.9	3
51	How Can Cancer-Associated Anemia Be Moderated with Nutritional Factors and How Do Beta Vulgaris L. Ssp. Esculenta Var. Rubra Modify the Transmethylation Reaction in Erythrocytes in Cancerous Patients?. , 0, , .		3
52	Bilateral renal cell carcinoma in a horseshoe kidney. <i>Pathology and Oncology Research</i> , 2002, 8, 270-271.	0.9	2
53	Chromosomal Aneuploidy in Azoospermic Men. <i>International Journal of Human Genetics</i> , 2006, 6, 171-176.	0.1	2
54	Real-time flow resistance compensation for urodynamic examinations of the upper urinary tract through single lumen catheters. <i>International Journal of Urology</i> , 2008, 15, 110-113.	0.5	2

#	ARTICLE	IF	CITATIONS
55	A novel quantitative method for measuring obstruction in the upper urinary tract: The "obstruction coefficient"™. International Journal of Urology, 2008, 15, 499-504.	0.5	2
56	Mucoepidermoid Lung Tumor Appearing as an Abscess on the Scrotum. Urologia Internationalis, 2009, 82, 122-124.	0.6	1
57	Re: B.J. De Castro and K. C. Baker: Effect of Flexible Cystoscopy on Serum Prostate-specific Antigen Values (Urology 2009; 73:237-240). Urology, 2009, 74, 234.	0.5	1
58	Re: A New Postoperative Predictor of Time to Urinary Continence after Laparoscopic Radical Prostatectomy: The Urine Loss Ratio. European Urology, 2007, 52, 1529-1530.	0.9	0
59	Diagnostic and treatment options in a papillary pelvic tumor patient with solitary kidney refusing nephrectomy. European Journal of Radiology Extra, 2009, 72, e17-e19.	0.1	0
60	Re: Post-Prostatectomy Urinary Incontinence: A Confluence of 3 Factors. European Urology, 2010, 58, 463-464.	0.9	0